A new UK company focused on developing small molecule drugs for rare neuromuscular and metabolic diseases is being prepared for launch following the publication of research on mitochondrial dysfunction in the journal, Proceedings of the National Academy of Sciences, USA. The company, MitoRx Therapeutics, is being spun out of the University of Exeter. Jon Rees, a life sciences consultant, has been named chief executive.
